Encepur Tick-Borne Encephalitis Vaccine Clinical Trials, Dosage, Safety 

Encepur® is a whole virus vaccine containing an inactivated and purified Tick-Borne Encephalitis (TBE) virus/strain prevalent in Central, Eastern, and Northern Europe. The World Health Organization (WHO) recommends vaccination for all age groups, including children, in areas where the disease is highly endemic. For children aged >1 year (ENCEPUR CHILDREN, 0.25 mL) and for Adults and children aged > 12 years (ENCEPUR ADULTS, 0.5 mL).

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines.

Encepur Vaccine Indication

Encepur is indicated for active immunization of high-risk populations against TBE. The WHO recommends considering the Tick-Borne encephalitis vaccine for travelers at higher risk of the disease, as vaccination offers the most effective protection, and recommends vaccinating all age groups, including children, in areas where the disease is highly endemic. As of Movember 2025, Encepur revenue grew by 15% in the first nine months compared to the prior year, driven by strong market growth and increased market shares.

Encepur Vaccine Dosage

Encepur is administered as an intramuscular injection. Its unique dosing flexibility is supported by proven efficacy and long-term persistence data. ENCEPUR's rapid schedule: immunisation completed in just 21 days.

Encepur Vaccine Booster

ENCEPUR booster protects those at ongoing risk of TBE and is recommended every 5 years for those aged 1-49 and every 3 years for those aged>49.

Encepur Vaccine Availability

As of 2025, Encepur is marketed only in European countries, with Germany as the largest market.

Encepur Vaccine News

May 9, 2025 - Bavarian Nordic A/S reported its interim financial results and business progress for the first three months of 2025. Revenue for the first three months increased by 62% to DKK 1,347 million.

October 21, 2019 - Bavarian Nordic announced that it has entered an agreement with GlaxoSmithKline to acquire the manufacturing and global rights to Encepur®.

Encepur Vaccine Clinical Trials

Clinical Trial NCT03294135: This Study aims to investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine.